A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 74 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patient meets DSM-IV-TR criteria for schizophrenia.
Patient is aged 18 through 74 years at informed consent.
Patient understands the objectives, procedures, and possible benefits and risks of the study and who provide written voluntarily consent to participate in the study
Patient has a history of neuroleptic malignant syndrome, water intoxication, or paralytic ileus.
Patient has Parkinson's disease.
Patient has a history or complication of malignancy.